Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2% - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price traded down 3.2% during trading on Tuesday . The stock traded as low as $0.37 and last traded at $0.39. 45,372,542 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 29,892,227 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They issued a "hold" rating for the company.

Tonix Pharmaceuticals Trading Down 4.4 %

The company has a 50-day moving average price of $0.21 and a 200 day moving average price of $0.41. The stock has a market capitalization of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.